Literature DB >> 28572460

Capecitabine Extends Survival for Biliary Tract Cancer.

.   

Abstract

Based on results of the phase III BILCAP study, adjuvant capecitabine should become standard treatment for patients with biliary tract cancer. Among 430 patients who were treated according to the study protocol, capecitabine was associated with a 25% lower risk of death than observation. ©2017 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28572460     DOI： 10.1158/2159-8290.CD-NB2017-079

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  6 in total

1.  Improved Survival in Surgically Resected Distal Cholangiocarcinoma Treated with Adjuvant Therapy: a Propensity Score Matched Analysis.

Authors:  Caitlin Hester; Ibrahim Nassour; Beverley Adams-Huet; Mathew Augustine; Michael A Choti; Rebecca M Minter; John C Mansour; Patricio M Polanco; Matthew R Porembka; Sam C Wang; Adam C Yopp
Journal:  J Gastrointest Surg       Date:  2018-07-20       Impact factor: 3.452

2.  Prognostic Nomogram Based on Histological Characteristics of Fibrotic Tumor Stroma in Patients Who Underwent Curative Resection for Intrahepatic Cholangiocarcinoma.

Authors:  Chu-Yu Jing; Yi-Peng Fu; Jin-Long Huang; Mei-Xia Zhang; Yong Yi; Wei Gan; Xin Xu; Hu-Jia Shen; Jia-Jia Lin; Su-Su Zheng; Juan Zhang; Jian Zhou; Jia Fan; Zheng-Gang Ren; Shuang-Jian Qiu; Bo-Heng Zhang
Journal:  Oncologist       Date:  2018-09-26

Review 3.  Liver Resection and Surgical Strategies for Management of Primary Liver Cancer.

Authors:  Sonia T Orcutt; Daniel A Anaya
Journal:  Cancer Control       Date:  2018 Jan-Mar       Impact factor: 3.302

4.  Optimal perioperative care in peri-hilar cholangiocarcinoma resection.

Authors:  Leonard M Quinn; Declan F J Dunne; Robert P Jones; Graeme J Poston; Hassan Z Malik; Stephen W Fenwick
Journal:  Eur Surg       Date:  2018-05-04       Impact factor: 0.953

5.  HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.

Authors:  Chu-Yu Jing; Yi-Peng Fu; Yong Yi; Mei-Xia Zhang; Su-Su Zheng; Jin-Long Huang; Wei Gan; Xin Xu; Jia-Jia Lin; Juan Zhang; Shuang-Jian Qiu; Bo-Heng Zhang
Journal:  J Immunother Cancer       Date:  2019-03-18       Impact factor: 13.751

6.  Surgical techniques and strategies for the treatment of primary liver tumours: hepatocellular and cholangiocellular carcinoma.

Authors:  Eva Braunwarth; Stefan Stättner; Margot Fodor; Benno Cardini; Thomas Resch; Rupert Oberhuber; Daniel Putzer; Reto Bale; Manuel Maglione; Christian Margreiter; Stefan Schneeberger; Dietmar Öfner; Florian Primavesi
Journal:  Eur Surg       Date:  2018-05-17       Impact factor: 0.953
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.